NHS to save millions on AMD treatment

A landmark ruling promises to substantially reduce the cost of treating wet age-related macular degeneration (AMD) – and has significant implications for future drug policy. Bayer and Novartis had attempted to stop clinical commissioning groups (CCGs) from prescribing Avastin – a widely used and cheaper treatment, but unlicensed for AMD.

In September, the High Court ruled against the drug giants.